Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NRX-101 outperforms lurasidone
February 2019
SHARING OPTIONS:

WILMINGTON, Del.—NeuroRx recently shared data from its Phase 2 STABIL-B study of NRX-101 vs. lurasidone in patients with severe bipolar depression and acute suicidal ideation and behavior (ASIB), which was also presented at the American Congress of Neuropsychopharmacology. The study showed a statistically significant 11-point difference on the Montgomery Åsberg Depression Rating Scale (MADRS) between NRX-101 and lurasidone groups at day 14, and patients who received NRX-101 maintained a lower depression score over the six weeks of the trial vs. patients on lurasidone. None of the NRX-101 patients relapsed, though two of the five lurasidone patients did. NRX-101 was well tolerated overall, with no serious adverse events or discontinuations, and demonstrated no evidence of abuse liability. NeuroRx is currently initiating a pivotal Phase 2b/3 study of NRX-101.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.